Summary
We report on 208 patients with locally advanced renal-cell carcinoma who received a surgical adjuvant vaccination with autologous, Newcastle disease virus (NDV)-modified, and lethally irradiated tumor cells in combination with low-dose recombinant interleukin-2 and interferon-alpha. The pathological stage was defined as pT2-3a, N1-2, MO (n=107); pT3b-4 NO, MO (n=68); and pT3b-4, N1-2, MO (n=23). The follow-up of 203 evaluable patients showed a median disease-free survival of 21+ months (range, 2–64+ months). In all, 18 relapses (9%) occurred in spite of initial vaccination therapy. Those patients presented with local relapse (n=3), lymph node metastases (n=10), and/or distant organ metastases (n=9). All patients relapsing during the first 6 months after the onset of treatment had primary lymph node involvement of the disease. An analysis of the patient subgroup with a follow-up of more than 22 months showed 10 relapses among 56 patients (18%) along with a median follow-up of 39 months (range, 23–64 months). Toxicity was very mild, manifesting as flu-like symptoms and fevers of up to 38°C. At 8 and 24 weeks after the start of vaccination, anti-NDV serum antibodies were detectable in 70% and 100% of the patients tested, respectively. In comparison with historical data based on the natural course of patients with locally advanced renal-cell cancer, our results demonstrate an improvement of the disease-free survival after surgical adjuvant treatment with autologous, NDV-modified tumor vaccines in combination with low-dose cytokines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bassil B, Dosoretz DE, Prout GR (1985) Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 134:450–454
Berd D, Maguire HC, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with autologous tumor-cell vaccines: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858–1867
Bystryn J-C, Oratz R, Henn M, Adler A, Harris MN, Roses DF (1992) Relationship between immune response to melanoma vaccine and clinical outcome in stage II malignant melanoma. Cancer 69:1157–1164
Cassel WA, Murray DR, Torbin AH, Olkowski ZL, Moore ME (1977) Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 40:672–679
Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of stage II malignant melanoma with Newcastle disease virus oncolysate. Cancer 52:856–860
Hanna MG, Key ME (1982) Immunotherapy of metastases enhances subsequent chemotherapy. Science 217:367–369
Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 144:238–241
Hoover Hc, Surdyke MG, Dangel RB, Peters LC, Hanna MG (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1236–1243
Kernion JB de (1986) Renal tumors. In: Walsh PC, Campbell MF (eds) Campbell's urology, 5th edn, vol 2. Saunders, Philadelphia, pp 1297–1342
Kirchner H, Körfer A, Franks CR, Evers P, Goldmann U, Knüver-Hopf J, Gessner S, Poliwoda H, Atzpodien J (1990) Subcutaneous interleukin-2 and interferon-a in patients with metastatic renal cell cancer: the German outpatient experience. Mol Biother 2:145–154
Madeiros LJ, Gelb AB, Weiss LM (1988) Renal cell carcinoma: Prognostic significance of morphologic parameters in 121 cases. Cancer 61:1639–1651
McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E (1993) Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann NY Acad Sci 690:349–351
O'Donnel RW, Marquis DM, Mudholkar GS, McCune CS (1986) In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines. Cancer Res 46:3273–3278
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Schärfe T, Becht E, Klippel KF, Jacobi GH, Hohenfellner R (1986) Active specific immunotherapy of stage IV renal cell carcinoma using autologous tumor cells. World J Urol 3:245–248
Schirrmacher V, Shantz G, Clauer K, Komitowski D, Zimmermann HP, Lohmann-Matthes ML (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation in vivo. Int J Cancer 23:233–244
Schirrmacher V, Hoegen P von, Schlag P, Liebrich W, Lehner B, Schumacher K, Ahlert T, Bastert G (1989) Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. In: Schirrmacher V, Schwartz-Albiez R (eds) Cancer metastasis. Springer, Berlin Heidelberg New York, pp 157–170
Towbin H, Staehelin J, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 76:4350–4354
Tykkä H, Oravisto KJ, Lehtonen T (1978) Active specific immunotherapy of advanced renal cell carcinoma. Eur J Urol 4:250–254
Zorn U, Dallmann I, Große J, Kirchner H, Poliwoda H, Atzpodien J (1994) Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9:225–235
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirchner, H.H., Anton, P. & Atzpodien, J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13, 171–173 (1995). https://doi.org/10.1007/BF00184874
Issue Date:
DOI: https://doi.org/10.1007/BF00184874